Chris E. Simmons

Array ( [id] => 19614818 [patent_doc_number] => 20240400498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => PRODRUGS OF ITACONATE AND METHYL ITACONATE [patent_app_type] => utility [patent_app_number] => 18/777888 [patent_app_country] => US [patent_app_date] => 2024-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16540 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18777888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19691189 [patent_doc_number] => 20250009734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => METHODS OF INHIBITING FOXO1 FOR TREATMENT OF LYMPHATIC DISORDERS [patent_app_type] => utility [patent_app_number] => 18/757228 [patent_app_country] => US [patent_app_date] => 2024-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18757228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418351 [patent_doc_number] => 20240294474 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF [patent_app_type] => utility [patent_app_number] => 18/644728 [patent_app_country] => US [patent_app_date] => 2024-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18644728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387814 [patent_doc_number] => 20240277684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION [patent_app_type] => utility [patent_app_number] => 18/638133 [patent_app_country] => US [patent_app_date] => 2024-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9934 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417252 [patent_doc_number] => 20240293375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS [patent_app_type] => utility [patent_app_number] => 18/629056 [patent_app_country] => US [patent_app_date] => 2024-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18629056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345161 [patent_doc_number] => 20240254124 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => AZAINDOLE ROCK INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/610051 [patent_app_country] => US [patent_app_date] => 2024-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31978 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18610051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19940218 [patent_doc_number] => 12312340 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-27 [patent_title] => Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins [patent_app_type] => utility [patent_app_number] => 18/590713 [patent_app_country] => US [patent_app_date] => 2024-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 149 [patent_figures_cnt] => 179 [patent_no_of_words] => 122370 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18590713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19673887 [patent_doc_number] => 12185722 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-01-07 [patent_title] => Emulsifiable concentrate (EC) formulation of nitenpyram [patent_app_type] => utility [patent_app_number] => 18/436569 [patent_app_country] => US [patent_app_date] => 2024-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 5 [patent_no_of_words] => 9082 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18436569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19201378 [patent_doc_number] => 20240173277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => ANTI-MYCOBACTERIAL DRUGS [patent_app_type] => utility [patent_app_number] => 18/388696 [patent_app_country] => US [patent_app_date] => 2023-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11367 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18388696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19090952 [patent_doc_number] => 11952382 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-04-09 [patent_title] => 2-benzo-[3,4-b]quinolino-[b,g]indeno[1,2:3,4]fluoreno-[1,2-d]oxonine-24-flouro-5,11,16,21-tetraone as an antimicrobial compound [patent_app_type] => utility [patent_app_number] => 18/387550 [patent_app_country] => US [patent_app_date] => 2023-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3898 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18387550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18995844 [patent_doc_number] => 11912671 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-02-27 [patent_title] => Ethyl 3-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4- triazol-3-ylthio)propanoate as an antimicrobial compound [patent_app_type] => utility [patent_app_number] => 18/382834 [patent_app_country] => US [patent_app_date] => 2023-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 4013 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18382834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19060097 [patent_doc_number] => 11939305 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-03-26 [patent_title] => Ethyl 2-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)acetate as an antimicrobial compound [patent_app_type] => utility [patent_app_number] => 18/489805 [patent_app_country] => US [patent_app_date] => 2023-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 4009 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18489805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018854 [patent_doc_number] => 20240075025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => Therapy for Mitochondrial Fatty Acid Beta-Oxidation and Transport Disorders [patent_app_type] => utility [patent_app_number] => 18/376188 [patent_app_country] => US [patent_app_date] => 2023-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11970 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18376188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067113 [patent_doc_number] => 20240101539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS [patent_app_type] => utility [patent_app_number] => 18/220737 [patent_app_country] => US [patent_app_date] => 2023-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 126764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18220737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18877372 [patent_doc_number] => 20240000741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => ALL-TRANS RETINOIC ACID ENHANCES RADIOTHERAPY AND OVERCOMES IMMUNE SUPPRESSION FOR CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 18/329289 [patent_app_country] => US [patent_app_date] => 2023-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18329289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19372872 [patent_doc_number] => 12064411 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-08-20 [patent_title] => Methods of administering solriamfetol to lactating women [patent_app_type] => utility [patent_app_number] => 18/323229 [patent_app_country] => US [patent_app_date] => 2023-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11664 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18323229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769302 [patent_doc_number] => 20230364060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS [patent_app_type] => utility [patent_app_number] => 18/321266 [patent_app_country] => US [patent_app_date] => 2023-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18321266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18752345 [patent_doc_number] => 20230355575 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/198058 [patent_app_country] => US [patent_app_date] => 2023-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18198058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246722 [patent_doc_number] => 20240197706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => METHODS OF IMPROVING THE PHARMACOKINETICS OF MIGALASTAT [patent_app_type] => utility [patent_app_number] => 18/315928 [patent_app_country] => US [patent_app_date] => 2023-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21939 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18315928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18595906 [patent_doc_number] => 20230270696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => MEDICINAL USE OF FINGOLIMOD IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY SPHINGOLIPID DISORDERS [patent_app_type] => utility [patent_app_number] => 18/314781 [patent_app_country] => US [patent_app_date] => 2023-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18314781 [rel_patent_id] =>[rel_patent_doc_number] =>)